Selection of patients for combination therapy
US11397184B2 · kind B2 · utility
2Cited by
0References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 2, 2016 |
| Grant date | Jul 26, 2022 |
| Priority date | — |
| Expiry date | Oct 18, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.